Mitchell Blutt is a New York City-based physician and investment professional. In 2005, following almost two decades of experience as an executive partner for JP Morgan Partners, he founded Consonance Capital, a groundbreaking healthcare investment firm based in New York City. Even with his busy schedule, Mitchell Blutt remains actively involved in the boards of companies and organizations, such as the National Venture Capital Association (NVCA). The NVCA considers itself to be the premier organization representing the country’s venture capital community. The organization empowers its members to fund today's most innovative entrepreneurs by advocating for policies that not only fortify innovation, but also rewards long-term investments. As an active advocate for its target community, NVCA was recently involved in reviewing an important foreign investment bill. The Foreign Investment Risk Review Modernization Act (FIRRMA) of 2017, was meant to expand the mandate of the Committee on Foreign Investment in the United States (CFIUS), enabling it to review minority investments in critical domestic technology companies. On behalf of the U.S. entrepreneurial ecosystem, the NVCA suggested several changes, including amending the passive investment exemption in the resolution, expanding exempted countries, and removing any stifling factors affecting foreign strategic investors. These proposed changes are meant to mitigate potential harm to U.S. startups, which rely on external funding to hit the ground running.
0 Comments
Leave a Reply. |
AuthorMaintaining an assortment of professional affiliations, Mitchell Blutt, MD, serves as founder and chief executive officer of Manhattan-based healthcare investment firm Consonance Capital. ArchivesCategories |